Editas Medicine, Inc. (LON:0IFK)
United Kingdom · Delayed Price · Currency is GBP · Price in USD | Market Cap | 313.44M +85.8% |
| Revenue (ttm) | 37.53M +7.4% |
| Net Income | -54.40M |
| EPS | -0.46 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 23,292 |
| Open | 2.800 |
| Previous Close | 2.930 |
| Day's Range | 2.480 - 2.810 |
| 52-Week Range | 1.671 - 3.940 |
| Beta | 2.00 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 10, 2026 |
About Editas Medicine
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated ... [Read more]
Financial Performance
In 2025, Editas Medicine's revenue was $40.52 million, an increase of 25.39% compared to the previous year's $32.31 million. Losses were -$160.06 million, -32.49% less than in 2024.
Financial numbers in USD Financial StatementsNews
Editas Medicine Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
EDIT-401’s non-human primate data showed 90% lower LDL-C, with effects durable through 10 months. First-cohort safety data are expected in Q1 2027, followed by top-line efficacy data in H2 2027.
Editas Medicine reports Q3 EPS (15c), consensus (21c)
Reports Q3 revenue $10.37M, consensus $4.53M. “We are incredibly excited by the progress we made in the third quarter as we advanced EDIT-401, our potentially best-in-class in vivo gene editing…
Editas Medicine Announces Third Quarter 2026 Results and Business Updates
Company received HREC approval to initiate Phase 1/2 Strive™ study of EDIT-401 in patients with hyperlipidemia in Australia New preclinical data presented at AHA Scientific Sessions demonstrating ≥90 ...
Editas Medicine Earnings release: Q3 2026
Editas Medicine released its Q3 2026 earnings on November 9, 2026, summarizing the period's financial results.
Editas Medicine Quarterly report: Q3 2026
Editas Medicine has published its Q3 2026 quarterly earnings report on November 9, 2026.
Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference
CAMBRIDGE, Mass., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today a...
Wells Fargo upgrades Editas Medicine after EDIT-401 study gets green light
As previously reported, Wells Fargo upgraded Editas Medicine (EDIT) to Overweight from Equal Weight with a price target of $6, up from $4, after the company announced it has received…
Editas Medicine upgraded to Overweight from Equal Weight at Wells Fargo
Wells Fargo upgraded Editas Medicine (EDIT) to Overweight from Equal Weight with a $6 price target
Editas Medicine receives approval to initiate clinical trial of EDIT-401
Editas Medicine (EDIT) announced it has received approval to initiate the Phase 1/2 Strive clinical trial of EDIT-401 in patients with Heterozygous Familial Hypercholesterolemia, or HeFH, in Australia...
Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia
Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering Company remains on track to begin patient dosing this year and report initial safety ...
Editas slips amid pressure on gene-editing sector after Anthropic update
Editas Medicine (EDIT) is trading lower alongside other gene editing peers after Anthropic shared early findings on a CRISPR like enzyme system. Anthropic said its Claude model autonomously identified...
Editas Medicine upgraded to Buy at Guggenheim on EDIT-401 potential
As previously reported, Guggenheim upgraded Editas Medicine (EDIT) to Buy from Neutral with a $5 price target Should clinical data confirm EDIT-401’s preclinical efficacy with acceptable safety, the f...
Editas Medicine upgraded to Buy from Neutral at Guggenheim
Guggenheim upgraded Editas Medicine (EDIT) to Buy from Neutral with a $5 price target
Editas Medicine Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
The company has fully pivoted to in vivo CRISPR therapeutics, with EDIT-401 targeting a 90% LDL cholesterol reduction and first patient dosing expected this year. Key clinical milestones include safety data in Q1 next year and top-line results in 2027, supported by a strong cash position into 2028.
Editas Medicine Reports Inducement Grants to New Chief Medical Officer
CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced t...
Editas Medicine Transcript: Wells Fargo 21st Annual Healthcare Conference
The company is advancing in vivo CRISPR therapies, with EDIT-401 targeting severe hypercholesterolemia by upregulating LDL receptors. Phase I trials will start in Australia this year, with safety data expected in Q1 2027 and U.S. entry planned for 2027. Cash runway extends into 2028.
Editas Medicine appoints Dan Ory as chief medical officer
Editas Medicine (EDIT) announced the appointment of Dan Ory as chief medical officer, effective immediately. Ory will oversee the company’s clinical development strategy and operations as Editas advan...
Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer
Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development
Editas Medicine to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today ...
Editas Medicine files $400M mixed securities shelf
16:27 EDT Editas Medicine (EDIT) files $400M mixed securities shelf
Editas Medicine Registration statement: Registration filing
Editas Medicine filed a registration statement on August 31, 2026, providing details about a securities offering with the SEC.
Editas Medicine initiated with a Buy at Ladenburg
Ladenburg initiated coverage of Editas Medicine (EDIT) with a Buy rating and $6 price target
Editas Medicine reports Q2 EPS (15c), consensus (28c)
Reports Q2 revenue $11.89M, consensus $2.75M. The revenue increase was primarily attributable to the recognition of deferred revenue related to the expiration certain rights to opt-in to additional re...
Editas Medicine Announces Second Quarter 2026 Results and Business Updates
EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins, incl...
Editas Medicine Earnings release: Q2 2026
Editas Medicine released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.